

# Clinical Note

**Patient Name:** David Brown

**Date of Birth:** 1970-09-10

**Date of Note:** November 18, 2025

## Diagnosis & Disease Status

**Primary Diagnosis:** Colon cancer

**ICD-10 Code:** C18.9

**Disease Stage:** Stage III (Note: Assumed based on prior FOLFOX chemotherapy)

**Performance Status:** ECOG 1 (Assumed)

## Clinical History

### Prior Therapies:

- FOLFOX or 5-FU chemotherapy

### Current Line of Therapy:

- Second-line or adjuvant

### Medication History:

- FOLFOX regimen (combination of oxaliplatin, leucovorin, and 5-fluorouracil)

## Biomarker & Laboratory Results

Biomarker / Test	Result	Comments
KRAS	Wild type	Eligible for anti-VEGF therapy

## Assessment & Plan

### Assessment:

Patient with Stage III colon cancer, status post-FOLFOX/5-FU chemotherapy. Biomarker testing indicates KRAS Wild type. Patient is a candidate for anti-angiogenic therapy in the second-line or adjuvant setting.

### Treatment Plan:

- **Planned Treatment:** Bevacizumab
- Initiate bevacizumab therapy as anti-angiogenic treatment in combination with chemotherapy as indicated.

- Monitor blood pressure, renal function, and proteinuria per bevacizumab safety guidelines.
- Continue surveillance for treatment response and toxicity.

## **Insurance Information**

Provider: Humana

Policy ID: INS33445

Coverage Period: 2025-01-01 to 2025-12-31

Eligibility Status: ACTIVE